YolTech Therapeutics Administers First Patient Dose of YOLT-203 in Clinical Trial for Groundbreaking In Vivo Gene Editing Therapy for PH1.

we will proceed with a specific sequence example to explore how nucleotide information can be efficiently retrieved using Patsnap Bio.

FDA Approves Pfizer-BioNTech's Updated COVID-19 Vaccine for Ages 12 and Up; Grants Emergency Use for Ages 6 Months to 11 Years.

The European Commission has granted approval for BALVERSA® (erdafitinib) in treating adults with advanced or metastatic urothelial cancer.

This trial is investigating OMX-0407, a first-in-class, spectrum-selective SIK (salt-inducible kinase) inhibitor, in patients with advanced solid tumors.

Skye Bioscience Initiates Phase 2 CBeyond Trial for its Unique CB1 Inhibitor Nimacimab in Obesity Patients.

Sutro Biopharma has initiated and is currently enrolling participants for its global Phase 2 trial, REFRαME-L1, which tests luveltamab tazevibulin (luvelta) in NSCLC patients with Folate Receptor-α expression.

Monopar Therapeutics revealed that it has obtained Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase 1 clinical trial for its innovative radiopharmaceutical MNPR-101-Lu.

8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

D&D Pharmatech begins Phase 2 trial for DD01, a long-lasting dual GLP-1/Glucagon receptor agonist, to assess its safety and efficacy in overweight/obese individuals with MASLD/MASH.

Aug 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) has had its second NDA accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC.